109 Participants Needed

Ibrutinib + Chemotherapy for CNS Lymphoma

Recruiting at 15 trial locations
Christian Grommes, MD profile photo
Ingo Mellinghoff, MD profile photo
Overseen ByIngo Mellinghoff, MD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I have to stop taking my current medications for the trial?

The trial requires that you stop taking certain medications before starting the study drug. Specifically, you must stop using warfarin or similar anticoagulants at least seven days prior, and any drugs that affect the P450/CYP3A enzyme at least two weeks prior. Additionally, you must stop systemic immunosuppressant therapy at least 28 days before the first dose.

What data supports the effectiveness of the drug Ibrutinib in treating CNS Lymphoma?

Research shows that Ibrutinib, when used alone or with chemotherapy, can significantly reduce tumors in patients with central nervous system lymphoma. In one study, 94% of patients showed tumor reductions with Ibrutinib alone, and 86% achieved complete remission when combined with chemotherapy.12345

Is the combination of Ibrutinib and chemotherapy safe for treating CNS lymphoma?

Ibrutinib, when used alone or with chemotherapy for CNS lymphoma, has shown some safety concerns, particularly an increased risk of aspergillosis (a type of fungal infection) due to its effect on the immune system. However, it has been generally well-tolerated in some patients, with one case showing good tolerance and sustained remission.12367

How does the drug ibrutinib differ from other treatments for CNS lymphoma?

Ibrutinib is unique because it is a Bruton's tyrosine kinase inhibitor, which means it works by blocking a specific protein that helps cancer cells grow. This mechanism is different from standard chemotherapy, which often cannot cross the blood-brain barrier to reach the central nervous system effectively.89101112

What is the purpose of this trial?

The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-line chemotherapy regimen rituximab, methotrexate, vincristine, and procarbazine (R-VMP) in order to further refine the first-line induction therapy for PCNSL, as observed by a superior CRR (complete response rate) (ARM D RECRUITING ONLY)

Research Team

Christian Grommes, MD - MSK Neuro ...

Christian Grommes, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults with primary or secondary central nervous system lymphoma who have had at least one prior CNS therapy (except for some newly diagnosed cases). They must understand the study and consent, have a certain level of physical function, adequate organ function, agree to use effective birth control, and not be pregnant. Exclusions include uncontrolled infections, certain drug interactions, severe heart conditions, inability to swallow capsules, among others.

Inclusion Criteria

My bilirubin levels are within the normal range, or slightly elevated due to Gilbert Syndrome.
Absolute neutrophil count (ANC) ≥ 0.75 x 109/L
My scans show my brain tumor is growing, or my spinal fluid test confirms lymphoma.
See 19 more

Exclusion Criteria

I have had a stem cell transplant from a donor.
I am not using other cancer drugs except for approved supportive care.
I've had recent cancer treatment or am still experiencing side effects.
See 22 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 4 cycles of therapy with Methotrexate, Rituximab, Vincristine, Procarbazine, and Ibrutinib. Ibrutinib is dosed at 560 mg daily, with a safety lead-in of 6 patients.

16 weeks
Multiple visits for each cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment, with progression-free survival assessed.

2 years

Dose Escalation

Establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent and in combination with high-dose Methotrexate (HD-MTX).

1 year

Treatment Details

Interventions

  • Ibrutinib
Trial Overview The trial tests Ibrutinib's effectiveness when added to an established chemotherapy regimen (rituximab + high-dose methotrexate + procarbazine) in patients with central nervous system lymphoma. It aims to improve complete response rates by refining first-line induction therapy.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSLExperimental Treatment4 Interventions
THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
Group II: Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSLExperimental Treatment3 Interventions
Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
Group III: Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSLExperimental Treatment3 Interventions
The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
Group IV: Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSLExperimental Treatment3 Interventions
This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).

Ibrutinib is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
  • Graft-versus-host disease
🇺🇸
Approved in United States as Imbruvica for:
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
  • Graft-versus-host disease
🇨🇦
Approved in Canada as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia
  • Marginal zone lymphoma
🇯🇵
Approved in Japan as Imbruvica for:
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma
  • Waldenström's macroglobulinemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

Pharmacyclics LLC.

Industry Sponsor

Trials
114
Recruited
13,800+

Dr. Maky Zanganeh

Pharmacyclics LLC.

Chief Executive Officer

Degree from Louis Pasteur University in Strasbourg, France; MBA from Schiller International University in France

Dr. Ellie Im

Pharmacyclics LLC.

Chief Medical Officer

MD from an unspecified institution

Janssen Biotech, Inc.

Industry Sponsor

Trials
30
Recruited
18,800+

Findings from Research

Ibrutinib treatment showed a high overall response rate of 75% in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), with a median progression-free survival of 4 months, indicating its efficacy in this aggressive cancer type.
Genomic analysis revealed that patients with simpler genetic variants and lower tumor mutation burdens (TMB) responded better to ibrutinib, suggesting that genomic profiling could help predict treatment outcomes and tailor therapies for CNS lymphoma patients.
The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.Wang, S., Zhu, Y., Qian, X., et al.[2023]
In a phase Ib study involving 18 patients with primary CNS lymphoma (PCNSL), 94% experienced tumor reductions with ibrutinib monotherapy, highlighting its efficacy, especially in patients with specific mutations (CD79B and MYD88) that enhance B cell receptor signaling.
While ibrutinib showed promising results in reducing tumors and enhancing chemotherapy effectiveness, there was an increased risk of aspergillosis, a fungal infection, indicating a potential safety concern linked to impaired fungal immunity due to BTK inhibition.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.Lionakis, MS., Dunleavy, K., Roschewski, M., et al.[2022]
A 77-year-old patient with primary central nervous system lymphoma (PCNSL) showed good tolerance and sustained remission after receiving ibrutinib as a consolidation therapy following high-dose methotrexate and rituximab plus temozolomide.
This case suggests that ibrutinib, a Bruton's tyrosine kinase inhibitor that can cross the blood-brain barrier, may be an effective option for elderly patients with PCNSL, but further studies are needed to confirm these findings.
Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.Du, S., Bota, D., Kong, XT.[2022]

References

The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants. [2023]
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. [2022]
Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy. [2022]
Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. [2022]
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. [2021]
Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network. [2021]
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. [2018]
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia. [2021]
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. [2021]
Management of CNS metastases in patients with EGFR mutation-positive NSCLC. [2020]
Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security